Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.
Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce.We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-06-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2882328?pdf=render |
| _version_ | 1818143989075804160 |
|---|---|
| author | Alexander Hoare Stephen J Kerr Kiat Ruxrungtham Jintanat Ananworanich Matthew G Law David A Cooper Praphan Phanuphak David P Wilson |
| author_facet | Alexander Hoare Stephen J Kerr Kiat Ruxrungtham Jintanat Ananworanich Matthew G Law David A Cooper Praphan Phanuphak David P Wilson |
| author_sort | Alexander Hoare |
| collection | DOAJ |
| description | Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce.We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains.If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies. |
| first_indexed | 2024-12-11T11:40:25Z |
| format | Article |
| id | doaj.art-d8babe41e2ae4a06a5ed57a02cde5e90 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T11:40:25Z |
| publishDate | 2010-06-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d8babe41e2ae4a06a5ed57a02cde5e902022-12-22T01:08:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-06-0156e1098110.1371/journal.pone.0010981Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.Alexander HoareStephen J KerrKiat RuxrungthamJintanat AnanworanichMatthew G LawDavid A CooperPraphan PhanuphakDavid P WilsonUniversal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce.We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains.If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies.http://europepmc.org/articles/PMC2882328?pdf=render |
| spellingShingle | Alexander Hoare Stephen J Kerr Kiat Ruxrungtham Jintanat Ananworanich Matthew G Law David A Cooper Praphan Phanuphak David P Wilson Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS ONE |
| title | Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. |
| title_full | Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. |
| title_fullStr | Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. |
| title_full_unstemmed | Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. |
| title_short | Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. |
| title_sort | hidden drug resistant hiv to emerge in the era of universal treatment access in southeast asia |
| url | http://europepmc.org/articles/PMC2882328?pdf=render |
| work_keys_str_mv | AT alexanderhoare hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT stephenjkerr hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT kiatruxrungtham hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT jintanatananworanich hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT matthewglaw hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT davidacooper hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT praphanphanuphak hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia AT davidpwilson hiddendrugresistanthivtoemergeintheeraofuniversaltreatmentaccessinsoutheastasia |